Results 141 to 150 of about 4,821 (183)

Edible Marine Red Alga <i>Gracilaria coronopifolia</i> as a Potential Functional Ingredient: Chemical Profiling and Metabolic Effects in Diet-Induced Obese Rats. [PDF]

Foods
Bahtiar A, Musyantika L, Wahyuni T, Utami RA, Siriamornpun S.   +4 more
europepmc   +1 more source

Signals arising from the gastrointestinal tract that affect food intake (Syömiseen vaikuttavat mahasuolikanavan signaalit) [PDF]

Purhonen, Anna-Kaisa
core  

Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care? [PDF]

Expert Opin Pharmacother
Johnston EK, Bird EM, Malhotra A, Harding CD.   +3 more
europepmc   +1 more source

EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism.

Horm Res Paediatr
Mathieu C, Meireles M, Pagotto U, Wabitsch M, Banerjee I, Bartolomé A, Battelino T, Beck J, Chiarelli F, De Leon DD, Dovč K, El Goch M, Galderisi A, Gevers E, Gillard P, Haliloglu B, Hoermann H, Mankovsky B, Mertens J, Mohnike K, Oram R, Pasquini T, Pearson E, Pieber TR, Polovina S, Raskin J, Roeper M, Ruck L, Estebanez MS, Tankova T, Thornton P, van Rossum EFC, Vukovic R, Worth C, Zachurzok A.   +34 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Structural insight into selectivity of amylin and calcitonin receptor agonists

Nature Chemical Biology, 2023
Amylin receptors (AMYRs), heterodimers of the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins, are promising obesity targets. A hallmark of AMYR activation by Amy is the formation of a 'bypass' secondary structural motif (residues S19-P25).
Jianjun Cao, Matthew J. Belousoff, Elliot Gerrard, Radostin Danev, Madeleine M. Fletcher, Emma Dal Maso, Herman Schreuder, Katrin Lorenz, Andreas Evers, Garima Tiwari, Melissa Besenius, Ziyu Li, Rachel M. Johnson, Denise Wootten, Patrick M. Sexton   +14 more
openaire   +4 more sources

Oral delivery of the amylin receptor agonist pramlintide

Peptide Science, 2023
Abstract Amylin receptor agonism safely benefit diabetic patients, reducing the insulin requirements and glycemic excursions. Pramlintide is the triple proline human amylin analogue first used as injectable drug, but lacking physico‐chemical compatibility when co‐formulated with insulin. Here, we report the design and characterization
Celimar Sinézia, Tháyna Sisnande, Luis Peña Icart, Luís Maurício T. R. Lima   +3 more
openaire   +1 more source

Amylin is an agonist of the renal porcine calcitonin receptor.

Endocrinology, 1994
The cloned renal porcine calcitonin (pCT) receptor cDNA expressed by transient transfection in COS-1 cells or stable transfection in HEK-293 cells was assayed for interaction with CT, amylin, and CT gene-related peptide. Both [125I]salmon CT ([125I]sCT) and [125I]rat amylin displayed specific binding to transfected cells, and in both cases, pCT and rat
P M, Sexton, S, Houssami, C L, Brady, D E, Myers, D M, Findlay   +4 more
openaire   +3 more sources

Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists

European Journal of Medicinal Chemistry, 2022
Pramlintide is an equipotent amylin analogue that reduces food intake and body weight in obese subjects and has been clinically approved as an adjunctive therapy for the treatment of adult diabetic patients. However, due to its extremely short half-life in vivo, a regimen of multiple daily administrations is required for achieving clinical ...
Raymond J. Patch, Rui Zhang, Suzanne Edavettal, Mark J. Macielag, Annette J. Eckardt, Jiali Li, Marie-Laure Rives, Wilson Edwards, Simon A. Hinke, Xi Qiu, Wenying Jian, Ondrej Libiger, Songmao Zheng, Jey Jeyaseelan, Yin Liang, Shamina M. Rangwala, James N. Leonard, Pamela Hornby   +17 more
openaire   +2 more sources

Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin

European Journal of Pharmacology, 2023
Pharmacotherapies for obesity and type 2 diabetes (T2D) are thought to bridge the gap between lifestyle modification and the weight loss obtained with bariatric surgery. Although the effect of monotherapies, namely amylin and glucagon-like peptide-1 receptor (GLP-1R) agonists, has shown great potential, combination therapy is now becoming a strategy to
Simone A. Melander, Anna Katri, Morten A. Karsdal, Kim Henriksen   +3 more
openaire   +2 more sources